Cytomegalovirus (CMV)
19
10
10
9
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 19 trials
100.0%
+13.5% vs benchmark
32%
6 trials in Phase 3/4
56%
5 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (19)
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections
A Study of Cytomegalovirus (CMV) Infection After Kidney Transplant in Adults in the United Kingdom
A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific Antibodies
A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea
A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection
A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium
A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
A Study of Maribavir in Adults and Children With Post-transplant Cytomegalovirus (CMV) Infection in Argentina
Comparison Diagnostic Tests for the Diagnosis of CYTOmegalovirus Organ Disease in Patients With intestinalBOweL Diseases
A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection
A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplant (SOT) Participants in Europe and Canada
A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada
A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants
Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Study of SHP620 (Maribavir) in Healthy Adults
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients